Artwork
iconShare
 
Manage episode 461543439 series 3635266
Content provided by Quest Diagnostics®. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Quest Diagnostics® or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of Results are In by Quest Diagnostics, Amanda Benson is joined by Dr. Michael Racke, Medical Director for Neurology at Quest Diagnostics, to discuss the groundbreaking role blood-based biomarkers play in assessing Alzheimer’s disease risk. Dr. Racke shares his expert insights on how these biomarkers are revolutionizing early risk detection and diagnosis, offering primary care physicians a proactive tool to identify Alzheimer’s before cognitive symptoms appear. From the evolution of Alzheimer's diagnostics to the practical application of plasma-based tests, Dr. Racke explains how integrating these tests into routine health visits can enable earlier interventions and better patient outcomes. He also discusses how blood-based biomarkers, in conjunction with digital cognitive assessments, are improving the sensitivity of Alzheimer’s screenings. This episode is a must-listen for anyone interested in the future of Alzheimer’s diagnostics and the power of early detection in cognitive health.

Follow Us
Twitter @QuestDX
Facebook @QuestDiagnostics
Instagram @QuestDiagnostics

LinkedIn @QuestDiagnostics

Presented by Quest Diagnostics
www.questdiagnostics.com

  continue reading

4 episodes